Last updated: July 1, 2026
Litigation summary for VALEANT PHARMACEUTICALS INT’L v. MYLAN PHARMACEUTICALS (2:15-cv-08180): what claims were brought, procedural posture, and what it means for generic entry risk
Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc., case no. 2:15-cv-08180, is a Hatch-Waxman patent infringement dispute filed in the U.S. District Court for the District of New Jersey. The action is associated with Valeant’s branded small-molecule portfolio and Mylan’s generic development and/or ANDA pathway, with infringement theories tied to one or more Orange Book-listed patents covering the drug/strength and/or formulation or method-of-use. The case sits within the common framework of Paragraph IV litigation following ANDA filing, making the practical issue whether Mylan could launch at risk or needed a settlement that delayed entry.
What this means for business decisions: the filing number and the forum identify it as a “generic entry risk” case tied to ANDA timing and patent/Exclusivity constraints. Without the case docket content (complaint, asserted patent list, claim charts, claim construction orders, Markman, summary judgment, and any final judgment/settlement), a complete infringement-and-patent-by-patent analysis cannot be stated from the docket identifier alone.
What patents were asserted in Valeant v. Mylan (2:15-cv-08180)?
Featured snippet answer: The asserted patent(s) cannot be identified from the case caption and docket number alone. A patent-by-patent infringement summary requires the complaint’s “List of Patents” and each asserted claim number.
What to extract from the complaint (to map to an Orange Book estate)
Key inputs needed to complete an actionable estate analysis:
- Title of the asserted patents and publication numbers
- Patent numbers and expiration dates
- Claim numbers asserted (independent and dependent scope)
- Alleged infringement theory (product, formulation, method-of-use, or process)
- ANDA paragraph IV basis and “no infringement”/“invalidity” defenses pled
Why Orange Book mapping controls outcomes
In Hatch-Waxman litigation, Valeant’s asserted list generally aligns with Orange Book patents tied to:
- the NDA product’s active ingredient(s)
- specific strengths and dosage forms
- any supplemental patents covering formulation, stability, polymorph, or manufacturing method
Without the asserted list, the “how strong is the patent estate” assessment cannot be made.
When was the case filed, and what were the ANDA timing implications?
Featured snippet answer: Filing as “2:15-cv-08180” places the case in 2015, consistent with Paragraph IV timing, but the exact ANDA filing date and 30-month stay trigger cannot be established from the docket number alone.
What timing usually drives the litigation calendar
A full procedural and business analysis requires:
- ANDA submission date and Paragraph IV notice date
- the 30-month stay start and end date
- any “launch at risk” events tied to FDA approval timing
- whether the case was consolidated or managed with other Valeant/Mylan matters
What the 30-month stay does to generic entry risk
Paragraph IV cases typically affect entry through:
- the statutory 30-month stay (if triggered)
- injunctions or settlement-driven non-entry commitments
- design-around routes if the generic enters by waiting out only certain patents
What procedural steps occurred in Valeant v. Mylan?
Featured snippet answer: The procedural posture (Markman, claim construction, motion practice, final disposition) cannot be confirmed from the docket identifier alone.
Docket events that determine litigation leverage
An investable view requires:
- Markman date and claim construction outcomes
- whether invalidity theories survived to summary judgment
- whether the court granted/denied preliminary injunction (rare but decisive if granted)
- final judgment entry date and whether it included:
- infringement findings for specific claims
- invalidity findings
- unenforceability findings
- dismissal or narrowing settlement
How claim construction changes “design-around” feasibility
For formulation or method-of-use patents, the claim construction dictates:
- whether a generic product falls within the construed ranges or steps
- whether “equivalents” remain available
- whether label carve-outs avoid infringement
What is the infringement theory: product, formulation, or method-of-use patents?
Featured snippet answer: The infringement theory cannot be determined from the docket identifier alone.
Product vs. formulation vs. method-of-use: decision points
- Product/device/dose form patents: entry depends on composition and whether the generic’s marketed product matches the literal claim.
- Formulation and stability patents: entry depends on process parameters, excipient selection, polymorph form, particle size, or stability-related constraints.
- Method-of-use patents: entry depends on label instructions, physician practice, and inducement facts.
Why method-of-use cases often create label-workarounds
If the asserted patents are method-of-use, the label and promotional instructions become central, and settlement often trades money for a specific non-infringing label position.
How strong was Valeant’s patent estate in this case?
Featured snippet answer: Strength cannot be quantified without:
- the asserted patent set
- claim scope
- prosecution history and prior art
- any final validity rulings
Litigation strength metrics typically used by counsel
- likelihood of surviving summary judgment
- technical defensibility of claim construction
- vulnerability of independent claims
- remaining patent term at the time of settlement or judgment
What an investor would map from the docket
- proportion of asserted claims found infringed or not
- percentage of patents dismissed on procedural grounds
- whether the court required significant claim narrowing
Did Mylan file an ANDA Paragraph IV, and what generic entry risks existed?
Featured snippet answer: Paragraph IV is strongly implied by the Hatch-Waxman posture, but the specific ANDA number, dosage form, and approval decision dates cannot be confirmed without docket filings.
Risk profile categories for Paragraph IV disputes
- Risk at launch: generic approval with litigation unresolved and no settlement
- Delayed entry: settlement or sustained injunction
- Design-around: generic changes route/formulation/label to avoid specific claims
What to evaluate for commercial impact once the product is identified
Business teams usually tie:
- expected launch date window
- exclusivity expiration vs. patent expiration
- probability of injunction or settlement
- likely settlement payment and commercial terms
What was the outcome: settlement, dismissal, injunction, or final judgment?
Featured snippet answer: The case outcome cannot be stated without the docket disposition documents (final judgment, settlement stipulation, or withdrawal).
Settlement vs. final judgment: what each implies for the patent landscape
- Settlement often indicates:
- a risk concession by the generic
- a negotiated entry date or non-entry
- sometimes a license-to-sell at a later date
- Final judgment provides:
- enforceability and validity determinations
- clear infringement scope for similar generics
How outcomes translate to next-generation generic strategy
If claims are narrowed through construction or invalidated:
- additional challengers may file sooner
- subsequent generics may “carve out” the invalidated feature
- label changes can enable earlier launch for method-of-use patents
What Orange Book status applied to this Valeant product at the time?
Featured snippet answer: Orange Book listings cannot be identified from the docket identifier alone.
What the Orange Book mapping would include
- listed patents by expiration
- patent types (drug substance, drug product, method of use)
- any pediatric exclusivity or 505(b)(2) linkage
- whether there were supplemental patents with later expiration
Which other parties or related cases could affect interpretation?
Featured snippet answer: Related cases cannot be established from the docket number alone.
How consolidation and co-pending cases change risk
In multi-patent Orange Book situations, outcomes often hinge on:
- parallel litigation with different defendants or different ANDAs
- coordinated claim construction across cases
- settlement structures that apply to the same product family
Key takeaways for generic entry, licensing, and litigation strategy
- The case caption and docket number identify a Hatch-Waxman style patent infringement action in 2015 in the District of New Jersey between Valeant and Mylan.
- A complete infringement and patent-estate analysis requires docket-backed specifics: asserted patent numbers, claim scope, procedural rulings, and the disposition (judgment vs. settlement).
- For business use, the immediate decision lever remains the asserted Orange Book patent list and the litigation outcome tied to Mylan’s ANDA pathway, because those determine launch timing, injunction exposure, and settlement-based entry dates.
FAQs
1) What is case number 2:15-cv-08180 in one line?
It is the U.S. District Court action between Valeant Pharmaceuticals International, Inc. and Mylan Pharmaceuticals Inc. filed in the District of New Jersey.
2) Is this a Hatch-Waxman Paragraph IV dispute?
Its Hatch-Waxman posture is consistent with Paragraph IV litigation, but the ANDA/Paragraph IV details require docket filings.
3) What determines generic launch timing in this kind of case?
The asserted Orange Book patents, claim construction outcomes, statutory stays, and any settlement or injunction disposition.
4) How do method-of-use patents change the risk?
They shift the risk to label, induced infringement, and physician-patient instructions as construed by the court.
5) Can settlement terms be inferred from the docket number?
No. Settlement dates, entry commitments, and license terms require the docket disposition documents.
References (APA)
- U.S. District Court for the District of New Jersey. Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc., Case No. 2:15-cv-08180.
